All In Biotech

NDA 018027 · Ani Pharms

Lithobid

Lithium Carbonate · Oral

Last checked: Nov 20, 2026Latest source record: Oct 13, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1979

Apr 27, 1979

Approved uses

1

Original approval plus efficacy supplements

Registered trials

246

60 Phase 3, 15 recruiting

FAERS reports

16,978

13,565 serious, 1,226 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy (see DOSAGE AND ADMINISTRATION ).

What it is approved for

From the label in effect Aug 24, 2026.

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 27, 1979 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • LITHOBID · LITHIUM CARBONATE 300MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lithium Carbonate" as an intervention, any sponsor and status, largest first.

All 246 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • toxicity to various agents1,252
  • drug ineffective1,156
  • tremor1,090
  • drug interaction1,015
  • nausea849
  • weight increased824
  • depression721
  • insomnia721
  • fatigue698
  • vomiting676
  • confusional state649
  • somnolence643

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004576
2005495
2006795
20071,046
2008755
2009866
2010842
20111,140
20121,430
2013509
2014413
2015632
2016720
2017604
2018730
2019690
2020693
2021772
2022749
2023727
2024661
2025600
2026533

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lithobid (Lithium Carbonate)

2024 spending

$1.1M

Beneficiaries

149

889 claims

Per beneficiary

$7,653

$12.42 per unit

View as table
YearSpending
2020$2,046,998
2021$1,804,008
2022$1,505,206
2023$1,422,181
2024$1,140,289

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 394 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.